Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.tps602
Abstract: TPS602Background: Adjuvant intravesical bacillus Calmette-Guerin (BCG) decreases disease recurrence and progression in people with high-risk, non-muscle invasive urothelial bladder cancer (NMIBC), ... read more here.
Keywords: bladder cancer; invasive urothelial; urothelial bladder; high risk ... See more keywords
High frequency of bladder cancer after nephroureterectomy: justification for adjuvant intravesical treatment?
Sign Up to like & getrecommendations! Published in 2018 at "Research and Reports in Urology"
DOI: 10.2147/rru.s164166
Abstract: Background Bladder recurrence after nephroureterectomy (NU) is common. However, there is no acceptable policy of adjuvant intravesical treatment after NU. Objective To assess the rate of bladder recurrence following NU and to identify the high-risk… read more here.
Keywords: recurrence; bladder; adjuvant intravesical; recurrence developed ... See more keywords